High MAST2 mRNA expression and its role in diagnosis and prognosis of liver cancer

Jiao, Yan; Li, Yanqing; Jiang, Peiqiang; Fu, Zhuo; Liu, Yahui

doi:10.1038/s41598-019-56476-x

Cited by 12 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finding promising biomarkers can accurately assess the prognosis and timely assist systemic treatment of liver cancer patients. Many researches have been seeking the diagnostic and prognostic biomarkers all the time [26][27][28][29][30][31][32][33][34][35][36][37]. Here, we first found that HN1 mRNA overexpressed in liver cancer.…”

Section: Discussionmentioning

confidence: 94%

HN1 as a diagnostic and prognostic biomarker for liver cancer

Liu

Yang

et al. 2020

Bioscience Reports

Self Cite

View full text Add to dashboard Cite

Background: The present study aimed to examine the diagnostic and prognostic value of HN1 in terms of overall survival (OS) and recurrence-free survival (RFS) in liver cancer and its potential regulatory signaling pathway. Methods: We obtained clinical data and HN1 RNA-seq expression data of liver cancer patients from The Cancer Genome Atlas database, and analyzed the differences and clinical association of HN1 expression in different clinical features. We uesd receiver-operating characteristic curve to evaluate the diagnosis capability of HN1. We analyzed and evaluated the prognostic significance of HN1 by Kaplan–Meier curves and Cox analysis. Gene Set Enrichment Analysis (GSEA) was used to identify signaling pathways related to HN1 expression. Results: HN1 mRNA was up-regulated in liver cancer, and was associated with age, histologic grade, stage, T classification, M classification, and vital status. HN1 mRNA had ideal specificity and sensitivity for the diagnosis (AUC = 0.855). Besides, the analysis of Kaplan–Meier curves and Cox model showed that HN1 mRNA was strongly associated with the overall survival and could be well-predicted liver cancer prognosis, as an independent prognostic variable. GSEA analysis identified three signaling pathways that were enriched in the presence of high HN1 expression. Conclusion: HN1 serves as a biomarker of diagnosis and prognosis in liver cancer.

show abstract

Section: Discussionmentioning

confidence: 94%

HN1 as a diagnostic and prognostic biomarker for liver cancer

Liu

Yang

et al. 2020

Bioscience Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our group has, after a long period of research, identified a variety of novel LC biomarkers [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]. This study confirmed that hepatic PDK2 levels were lower in cancerous tissue than in normal tissue.…”

Section: Discussionmentioning

confidence: 55%

PDK2: a novel diagnostic and prognostic biomarker for liver cancer

Liu

Jiao

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Liver cancer (LC) is a common malignancy with very high morbidity. Pyruvate dehydrogenase kinases (PDKs) are regulators of mitochondrial pyruvate dehydrogenase complexes (PDCs) and play an important role in regulating cellular energy metabolism. In this study, The Cancer Genome Atlas (TCGA) database was used to analyze the expression of PDK2 mRNA in LC, and to explore the value of PDK2 in the diagnosis and prognosis of LC.Methods: The TCGA database, containing the clinical data of 373 LC patients, includes information on PDK2 expression values. The receiver operating characteristic (ROC) curve of PDK2 was drawn to evaluate its diagnostic ability. Patients were divided into PDK2 high- and low-expressing groups by threshold levels. The Chi-square test was used to evaluate the correlation between PDK2 levels and clinicopathological characteristics. The Kaplan-Meier estimator and Cox regression analysis were performed to assess the effect of PDK2 levels on survival outcomes.Results: PDK2 expression in LC tissue was lower than that in normal liver tissues. According to the area under the curve (AUC) value calculated by ROC, PDK2 has a considerable diagnostic value for LC prognosis. The decreased expression of PDK2 is associated with clinical parameters, such as histologic grade ( P =0.0001), radiation therapy ( P =0.0490), vital status ( P =0.0240), and overall survival (OS) ( P =0.0222). Multivariate analysis shows that decreased PDK2 level is an independent risk factor for predicting poor prognosis in LC.Conclusions: PDK2 has a significant impact on the prognosis of LC and is a potential biomarker for the diagnosis and prognosis of LC.

show abstract

“…Our laboratory has also been committed to the study of cancer biomarkers for patient prognosis. 18–21 In this study, we found that HK1 participates in the glycolysis of OC cells and may be an independent biomarker for the poor prognosis of OC patients.…”

Section: Discussionmentioning

confidence: 59%

<p>Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer</p>

Li¹,

Tian²,

Luo³

et al. 2020

OTT

Self Cite

View full text Add to dashboard Cite

Purpose Ovarian cancer (OC) has the highest mortality among gynecological malignancies. Therefore, it is urgent to explore prognostic biomarkers to improve the survival of OC patients. One of the most prominent metabolic characteristics of cancer is effective glycolysis. Hexokinase 1 (HK1), as the first rate-limiting enzyme in glycolysis, is closely related to cancer progression. However, the role of HK1 in OC remains unclear. Materials and Methods The Cancer Genome Atlas (TCGA) database was used to detect the expression of HK1 in OC patients. The chi-squared test was performed to examine the correlations between HK1 and patients’ clinical characteristics. Survival analyses were undertaken to determine the relationship between HK1 and patient survival, while the univariate/multivariate Cox model was used to evaluate the role of HK1 in patient prognosis. Gene Set Enrichment Analysis (GSEA) was performed to ascertain the related signaling pathways of HK1. RT-qPCR was implemented to validate the mRNA expression of HK1 in OC cells. MTT was used to detect cell viability after adding 2DG and knocking down HK1 in OC cells. HK1 protein expression was examined by Western blotting. Glucose uptake, lactate production, and ATP assays were undertaken following knockdown of HK1 in OC cells. Colony formation assays were performed to determine OC cell proliferation after HK1 knockdown. Transwell and wound healing assays were carried out to detect the invasion and migration of OC cells after HK1 knockdown. Results We found that HK1 expression was increased in OC tissues and cells, and HK1 was related to the clinical characteristics of OC patients. Survival analysis revealed that OC patients in the HK1 overexpression group had poor survival. Moreover, univariant/multivariate analyses showed that HK1 may be an independent biomarker for the poor prognosis of OC patients. OC cell viability and proliferation decreased after knockdown of HK1 . Consistently, glucose uptake, lactic acid production, ATP production, invasion, and migration were also decreased. Finally, GSEA enrichment analysis and Western blotting showed that HK1 was involved in MAPK/ERK signaling. Conclusion HK1 may be a biomarker for the poor prognosis of OC patients and a potential therapeutic target.

show abstract

High MAST2 mRNA expression and its role in diagnosis and prognosis of liver cancer

Cited by 12 publications

References 23 publications

HN1 as a diagnostic and prognostic biomarker for liver cancer

HN1 as a diagnostic and prognostic biomarker for liver cancer

PDK2: a novel diagnostic and prognostic biomarker for liver cancer

<p>Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer</p>

Contact Info

Product

Resources

About